On December 7, 2016, the Company entered into a Settlement Agreement with WuXi AppTec, Inc. (“WuXi”) relating to the Company’s termination of the WuXi Agreement, which termination was effective on August 1, 2016. The Settlement Agreement settles all of the Company’s obligations related to the termination of the WuXi Agreement. Under the Settlement Agreement, the Company is obligated (i) to make a payment of $5,400,000 in cash and (ii) to transfer all right, title and interest in certain equipment related to the WuXi Agreement to Wuxi. The Company had previously accrued an estimate of the expense of the Settlement Agreement in the second quarter of 2016 in connection with its announced restructuring, and expects to pay such amount before December 31, 2016.

About NewLink Genetics Corporation (NASDAQ:NLNK)

NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system. Algenpantucel-L is its clinically advanced product candidate for patients with pancreatic cancer. Its additional HyperAcute cellular HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma. It has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system’s tolerance to cancer.

NewLink Genetics Corporation (NASDAQ:NLNK) Recent Trading Information

NewLink Genetics Corporation (NASDAQ:NLNK) closed its last trading session down -0.08 at 10.60 with 183,957 shares trading hands.